AdultPediatricGeriatricDosage Forms & Strengths tablet, extended-release 15mg Rheumatoid Arthritis Indicated for moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to ≥1 tumor necrosis factor (TNF) blockers 15 mg PO qDay Psoriatic Arthritis Indicated for active psoriatic arthritis (PsA) in adults who have had an inadequate response or intolerance to ≥1 TNF blockers 15 mg PO qDay Atopic Dermatitis Indicated for refractory moderate-to-severe atopic dermatitis (AD) in adults whose disease is not adequately controlled with other systemic therapies or if those therapies are inadvisable <65 years 15 mg PO qDay initially; consider increasing to 30 mg qDay if an adequate response is not achieved Discontinue if 30-mg dose if adequate response not achieved Use lowest effective dose needed to maintain response Ulcerative Colitis Indicated for moderate to severe active ulcerative colitis (UC) in adults who had inadequate response or intolerance to ≥1 TNF blocker Induction: 45 mg PO qDay x 8 weeks Maintenance 15 mg PO qDay Refractory, severe, or extensive disease: Consider 30 mg qDay Use lowest effective dosage needed to maintain response Discontinue if unable to achieve adequate therapeutic response with 30 mg/day Ankylosing Spondylitis Indicated for active ankylosing spondylitis (AS) in adults who have had an inadequate response or intolerance to ≥1 TNF blockers 15 mg PO qDay Nonradiographic Axial Spondyloarthritis Indicated for active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy 15 mg PO qDay Crohn Disease Indicated for moderately-to-severely active Crohn disease in adults who have had an inadequate response or intolerance to ≥1 TNF blockers Induction: 45 mg PO qDay x 12 weeks Maintenance: 15 mg PO qDay; consider 30 mg qDay for patients with refractory, severe, or extensive disease Discontinue if unable to achieve an adequate therapeutic response with 30-mg dosage Use lowest effective dose needed to maintain response Dosage Modifications Coadministration of strong CYP3A4 inhibitors RA, PsA, AD, AS, or nr-axSpA: 15 mg PO qDay UC: 30 mg qDay x 8 weeks for induction, then 15 mg qDay for maintenance CD: 30 mg qDay x 12 weeks for induction, then 15 mg qDay for maintenance Infection If serious infection (eg, serious opportunistic infections) develops, interrupt treatment until infection is controlled Dose interruption for laboratory abnormalities Absolute neutrophil count (ANC) <1000 cells/mm3: Interrupt; may restart once ANC >1000 cells/mm3 Absolute lymphocyte count (ALC) <500 cells/mm3: Interrupt; may restart once ALC >500 cells/mm3 Hemoglobin (Hb) <8 g/dL: Interrupt; may restart once Hb >8 g/dL Hepatic transaminases: Interrupt if drug-induced liver injury suspected Renal impairment RA, PsA, AS, or nr-axSpA Mild (eGFR 60 to < 90 mL/min/1.73 m2), moderate (eGFR 30 to < 60 mL/min/1.73 m2), severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2): No dose adjustment necessary ESRD: Not studied AD Mild or moderate (eGFR >30 mL/min/1.73 m2): No dose adjustment necessary Severe (eGFR <30 mL/min/1.73 m2): 15 mg PO qDay ESRD: Not studied UC Mild or moderate (eGFR >30 mL/min/1.73 m2): No dose adjustment necessary Severe (eGFR 15 to <30 mL/min/1.73 m2): 30 mg qDay x 8 weeks for induction, then 15 mg qDay for maintenance ESRD (eGFR <15 mL/min/1.73 m2): Not recommended Crohn disease Mild-to-moderate (eGFR ≥30 mL/min/1.73m2): No dosage adjustment necessary Severe (eGFR 15 to <30 mL/min/1.73m2): 30 mg qDay for 12 weeks for induction; 15 mg qDay for maintenance ESRD (eGFR ≥30 mL/min/1.73m2): Not recommended Hepatic impairment RA, PsA, AS, nr-axSpA, or AD Mild or moderate (Child-Pugh A or B): No dose adjustment required RA, PsA, AS, nr-axSpA, UC, CD, or AD Severe (Child-Pugh C): Not recommended UC Mild or moderate (Child-Pugh A or B): 30 mg qDay x 8 weeks for induction, then 15 mg qDay for maintenance Severe (Child-Pugh C): Not recommended Crohn disease Mild-to-moderate (Child-Pugh A or B): 30 mg qDay for 12 weeks for induction; 15 mg qDay for maintenance Severe (Child Pugh C): Not recommended Dosing Considerations ALC <500 cells/mm3, ANC <1000 cell/mm3, or Hb <8 g/dL: Do not initiate Before initiating Test for tuberculosis (TB) before initiating; initiate antitubercular treatment for previously untreated latent TB or active TB before initiating treatment Verify pregnancy status in females of reproductive potential before initiating Screen viral hepatitis in accordance with clinical guidelines Update immunizations according to current immunization guidelines Limitations of use RA, PsA, AS or nr-axSpA: Use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants (eg, azathioprine, cyclosporine), is not recommended AD: Not recommended in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants UC, CD: Not recommended in combination with other JAK inhibitors, biological therapies, or potent immunosuppressants (eg, azathioprine, cyclosporine) Dosage Forms & Strengths tablet, extended-release 15mg Atopic Dermatitis Indicated for refractory moderate-to-severe atopic dermatitis (AD) in adults and pediatric patients aged ≥12 years whose disease is not adequately with other systemic therapies or if those therapies are inadvisable ≥12 years and >40 kg 15 mg PO qDay initially; consider increasing to 30 mg qDay if an adequate response is not achieved Discontinue if 30-mg dose if adequate response not achieved Use lowest effective dose needed to maintain response Dosage Modifications Coadministration of strong CYP3A4 inhibitors: 15 mg PO qDay Infection If serious infection (eg, serious opportunistic infections) develops, interrupt treatment until infection is controlled Renal impairment RA, AS, and PsA Mild, moderate, or severe: No dose adjustment necessary ESRD: Not studied AD Mild or moderate (CrCl >30 mL/min): No dose adjustment necessary Severe (CrCl <30 mL/min): 15 mg PO qDay ESRD: Not studied Hepatic impairment RA, PsA, AS, AD Mild or moderate (Child-Pugh A or B): No dose adjustment required Severe (Child-Pugh C): Not recommended Ulcerative Colitis (Orphan) Orphan designation for treatment of pediatric ulcerative colitis Sponsor AbbVie; 1 North Waukegan Road; North Chicago, Illinois 60044 Dosing Considerations Before initiating Test for tuberculosis (TB) before initiating; initiate antitubercular treatment for previously untreated latent TB or active TB before initiating treatment Verify pregnancy status in females of reproductive potential before initiating Screen viral hepatitis in accordance with clinical guidelines Update immunizations according to current immunization guidelines Limitations of use RA or PsA: Use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants (eg, azathioprine, cyclosporine), is not recommended AD: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants Atopic Dermatitis Indicated for refractory moderate-to-severe atopic dermatitis (AD) in adults whose disease is not adequately with other systemic therapies or if those therapies are inadvisable ≥65 years: 15 mg PO qDayInteraction CheckerEnter a drug name and upadacitinibNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (26)abataceptabatacept, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.abrocitinibabrocitinib, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.adalimumabadalimumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.alemtuzumabalemtuzumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.antithymocyte globulin equineantithymocyte globulin equine, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.avacopanavacopan, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.azathioprineazathioprine, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.baricitinibbaricitinib, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.basiliximabbasiliximab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.belataceptbelatacept, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.belimumabbelimumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.brodalumabbrodalumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.canakinumabcanakinumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.certolizumab pegolcertolizumab pegol, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.cyclosporinecyclosporine, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.eculizumabeculizumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.efgartigimod alfaefgartigimod alfa, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.efgartigimod/hyaluronidase SCefgartigimod/hyaluronidase SC, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.emapalumabemapalumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.etanerceptetanercept, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.fingolimodfingolimod, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.golimumabgolimumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.guselkumabguselkumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.infliximabinfliximab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.ozanimodozanimod, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.rozanolixizumabrozanolixizumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.Serious - Use Alternative (77)abametapirabametapir will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.adenovirus types 4 and 7 live, oralupadacitinib decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.amobarbitalamobarbital will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.anakinraanakinra, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.apalutamideapalutamide will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.axicabtagene ciloleucelupadacitinib, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.BCG vaccine liveupadacitinib decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.bosentanbosentan will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.brexucabtagene autoleucelupadacitinib, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.butabarbitalbutabarbital will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.butalbitalbutalbital will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.carbamazepinecarbamazepine will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.ceritinibceritinib will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.cholera vaccineupadacitinib decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.ciltacabtagene autoleucelupadacitinib, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.dabrafenibdabrafenib will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.dengue vaccineupadacitinib decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.efavirenzefavirenz will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.enzalutamideenzalutamide will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.etravirineetravirine will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.fexinidazolefexinidazole will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fosphenytoinfosphenytoin will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.idecabtagene vicleucelupadacitinib, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.inebilizumabinebilizumab, upadacitinib.